© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Higher Community Wellbeing Linked to Reduced CVD Mortality in Study of More than 3000 US Counties
July 06, 2023
Wellbeing is considered a measurable and modifiable community attribute that study authors show is correlated with CV outcomes.
US Maternal Mortality Doubled 1999-2019, Remains Highest Among Black Women
July 05, 2023
The greatest increase over the 10 years was seen in deaths among American Indian and Alaska Native women, according to Institute for Health Metrics and Evaluation data.
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
July 05, 2023
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
Pegozafermin Shows Early Promise in NASH: Phase 2b ENLIVEN Trial Findings
June 30, 2023
Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.
FDA Awards De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Decline in Kidney Function in Adults with Type 2 Diabetes and Early-Stage Kidney Disease
June 30, 2023
KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.
E-Cigarettes: US Sales Nearly Double over 2 Years, Youth Prefer Flavored Disposables
June 29, 2023
Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.
Studies of Novel, Highly Effective Antiobesity Medications Headline 83rd ADA Scientific Sessions
June 28, 2023
Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
June 27, 2023
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
June 27, 2023
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
June 26, 2023
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.